Phase 1 Study of Pemetrexed and Bevacizumab Intrathecal Injection for Treating Leptomeningeal Metastases in Non-Small Cell Lung Cancer
Led by Shanghai Chest Hospital · Updated on 2026-03-02
19
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining two drugs, pemetrexed and bevacizumab, delivered directly into the spinal fluid for patients with leptomeningeal metastases caused by non-small cell lung cancer NSCLC. This phase Ia clinical study aims to gather early data on how well this treatment works and its safety in this specific group of cancer patients who have limited options due to cancer spread in the brain and spinal cord membranes.
Participants receive intrathecal injections of pemetrexed twice a week for one week, then once every four weeks. Bevacizumab is given once during the first week with gradually increasing doses, then once every four weeks afterward. The study has two treatment groups one receiving pemetrexed alone and the other receiving both pemetrexed and bevacizumab. This approach allows researchers to compare the combination treatment with pemetrexed alone.
During the study, patients will be monitored for side effects and treatment safety from the start of treatment until two months after. Researchers will also track overall survival for up to two years. Participants will undergo regular evaluations including clinical assessments, laboratory tests, and imaging as needed. The total duration and follow-up depend on individual patient progress, with safety and effectiveness carefully observed throughout the study period.
CONDITIONS
Brief Title
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Research Team
H
Hua Zhong, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ECOG performance status score between 0 and 3, with scores of 2 or 3 due to leptomeningeal metastases
Pathologically confirmed non-small cell lung cancer with leptomeningeal metastases diagnosed by cerebrospinal fluid analysis and/or MRI
Disease progression or neurological worsening of leptomeningeal metastases despite standard systemic anti-tumor treatment
Expected survival time of at least 1 month
Laboratory tests showing hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L; total bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 2.5 times the upper limit of normal; creatinine ≤ 2.0 times the upper limit of normal or creatinine clearance ≥ 50 mL/min
Females of child-bearing potential must agree to use contraception during the study and for 6 months after, have a negative pregnancy test within 7 days before enrollment, and not be breastfeeding; males must agree to use contraception during the study and for 6 months after
Ability to understand and sign the informed consent form
You will not qualify if you...
Positive for human immunodeficiency virus (HIV)
Allergy to pemetrexed or bevacizumab
Previous intrathecal injection of pemetrexed and/or bevacizumab
Contraindications to bevacizumab including uncontrolled hypertension, significant proteinuria, unstable angina, recent myocardial infarction, severe heart or vascular disease, major hemoptysis within the past month, coagulation disorders, serious non-healing wounds or ulcers, abdominal fistula or gastrointestinal perforation, macrovascular invasion, or certain neurological disorders unrelated to tumors
Brain or spinal cord radiation therapy within 1 week before enrollment
Pregnant or lactating females
Refusal to use contraception during the study period
Any condition considered unsuitable for enrollment by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 years
Participants receive intrathecal injections of pemetrexed twice in the first week and once every 4 weeks thereafter. Bevacizumab is administered intrathecally once in the first week and then once every 4 weeks with dose escalation.
Multiple visits according to injection schedule: twice in first week and once every 4 weeks thereafter
Follow-up
Duration - Up to 2 years
Participants are monitored for safety and overall survival up to 2 years after treatment begins.
Visits continue for safety and survival monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 12 Study of Inhaled KB707 for Treating Advanced Solid Tumors in the Lungs with or without Keytruda and Chemotherapy
Phase II Study of Combined Neoadjuvant Chemotherapy, Chemoradiotherapy, and Dual Immune Checkpoint Blockade for Locally Advanced Non-Small Cell Lung Cancer
Study of Oral JBI-802 Alone or With Pembrolizumab for Advanced Non-Small Cell Lung Cancer With STK11 Mutation
First-in-Human Study Evaluating PHN-012 Antibody-Drug Conjugate in Advanced Solid Tumors Including Colon, Lung, and Pancreatic Cancer
Phase I Study of SH009 Injection Treatment for Adults With Advanced Solid Tumors Evaluating Safety, Effectiveness, and Drug Behavior
Phase II Study of Intraventricular Pemetrexed and Nivolumab for Treating Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
Phase I Study of TJ101 Antibody-Drug Conjugate to Assess Safety, Dosage, and Effectiveness in Adults With Advanced or Metastatic Solid Tumors
Evaluating Visual Feedback in Inspiratory Muscle Training
During Recovery After Lung Cancer Lobectomy
Using SHOX2 and PTGER4 Gene Methylation to Monitor Minimal Residual Disease and Predict Recurrence in Post-Surgery Non-Small Cell Lung Cancer Patients
Study of SHOX2 and PTGER4 Methylation Markers for Monitoring Recurrence Risk
in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Co-ablation Therapy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial.